|
|||||
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Home healthcare provider Addus HomeCare (NASDAQ:ADUS) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 20.3% year on year to $337.7 million. Its non-GAAP profit of $1.42 per share was 6.5% above analysts’ consensus estimates.
Is now the time to buy ADUS? Find out in our full research report (it’s free).
Addus HomeCare’s first quarter results for 2025 reflected the continued expansion of its Personal Care segment, supported by successful caregiver hiring and the full integration of the Gentiva acquisition. Management attributed the company’s revenue growth to higher service volumes, particularly in core states like Illinois, where reimbursement rates increased. CEO Dirk Allison emphasized, “We saw Personal Care hiring at 79 hires per day, up one hire per business day compared to the first quarter of 2024.”
Looking ahead, management highlighted ongoing acquisition opportunities and efforts to build density in existing markets, especially Texas, as key to sustaining growth. With state-level reimbursement dynamics and operational efficiency initiatives in focus, CFO Brian Poff stated, “We are well positioned to execute our acquisition strategy and expect our adjusted EBITDA margin percentage for the full year to remain above 12%.” Management also noted that legislative developments in Texas and further technology rollouts could impact future performance.
Addus HomeCare’s management cited several operational and market factors behind Q1’s financial outcomes and laid out ongoing priorities for future growth. Lower-than-expected revenue was attributed to transitional dynamics after the Gentiva acquisition and state-level Medicaid redeterminations, while margin performance reflected both organic growth and cost discipline.
Management’s outlook for the rest of the year centers on acquisition-driven expansion, continued hiring in Personal Care, and state reimbursement trends. The company expects its adjusted EBITDA margin to remain stable with further operational efficiencies and ongoing technology investments.
Looking ahead, the StockStory team will be monitoring (1) the outcome of Texas’ legislative session for potential reimbursement rate increases, (2) the pace and integration success of future acquisitions, particularly in high-density markets, and (3) the broader rollout and adoption rates of workforce management technology across more states. Progress in clinical labor retention and further improvements in hospice census will also be key markers for tracking Addus’ execution.
Addus HomeCare currently trades at a forward P/E ratio of 18×. Should you double down or take your chips? The answer lies in our free research report.
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
| Dec-30 | |
| Dec-26 | |
| Dec-24 | |
| Dec-24 | |
| Dec-11 | |
| Dec-11 | |
| Nov-24 | |
| Nov-24 | |
| Nov-18 | |
| Nov-10 | |
| Nov-05 | |
| Nov-04 | |
| Nov-04 | |
| Nov-03 | |
| Nov-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite